Table 1.
Patient demographic and clinical characteristics
| Number of patients (n = 48) | (%) | |
|---|---|---|
|
Age |
|
|
| Median |
76 |
|
| Min-Max |
70–86 |
|
|
Sex |
|
|
| Male |
24 |
50.0 |
| Female |
24 |
50.0 |
|
Performance status (WHO) |
|
|
| 0 |
11 |
22.9 |
| 1 |
33 |
68.8 |
| 2 |
4 |
8.3 |
|
Previous Treatment |
|
|
| Surgery |
36 |
75.0 |
| Adjuvant chemotherapy |
9 |
18.8 |
| Adjuvant radiotherapy |
4 |
8.3 |
|
Disease Sites |
|
|
| Lymph nodes |
15 |
31.3 |
| Liver |
36 |
75.0 |
| Lung |
17 |
35.4 |
| Other |
11 |
23 |
|
Number of Metastatic Sites |
|
|
| 1 |
22 |
45.8 |
| 2 |
14 |
29.2 |
| 3 |
10 |
20.8 |
| 4 |
1 |
2.1 |
|
CGA (n = 48) |
|
|
| Fit |
25 |
52.0 |
| Vulnerable |
23 |
48.0 |
|
GDS (n = 30) |
|
|
| ≤5 |
22 |
73.3 |
| >5 |
8 |
26.7 |
| Median |
4 |
|
| Range |
1–12 |
|
|
MMSE (n = 32) |
|
|
| <24 |
4 |
12.5 |
| ≥24 |
28 |
27.5 |
| Median |
27 |
|
| Range |
3–30 |
|
|
IADL (n = 37) |
|
|
| <7 |
10 |
73.3 |
| 7–8 |
27 |
26.7 |
| Median |
8.0 |
|
| Range |
3–8 |
|
|
Charlson Comorbidity Index |
|
|
| Median |
1 |
|
| Range |
0–2 |
|
|
Body Mass Index |
|
|
| Median |
27.75 |
|
| Range |
18.0–35.0 |
|
|
Haemoglobin (gr/dL) |
|
|
| Median |
11.8 |
|
| Range |
9.7–16.4 |
|
|
Albumin (gr/dL) |
|
|
| Median |
3.9 |
|
| Range |
2.6–4.8 |
|
|
Medications |
|
|
| Median |
1 |
|
| Range | 0–4 |